Search

Your search keyword '"Chi, Pei-Dong"' showing total 13 results
Start Over Author "Chi, Pei-Dong" Publication Year Range Last 10 years
13 results on '"Chi, Pei-Dong"'

4. An Immune Risk Score Predicts Survival of Patients with Acute Myeloid Leukemia Receiving Chemotherapy

Author

Wang, Yun, primary, Cai, Yan-yu, additional, Herold, Tobias, additional, Nie, Run-cong, additional, Zhang, Yu, additional, Gale, Robert Peter, additional, Metzeler, Klaus H., additional, Zeng, Yun, additional, Wang, Shun-qing, additional, Pan, Xue-yi, additional, Yang, Tong-hua, additional, Wu, Yuan-bin, additional, Zhang, Qing, additional, Wuxiao, Zhi-jun, additional, Du, Xin, additional, Liang, Zhi-wei, additional, Su, Yong-zhong, additional, Xu, Jing-bo, additional, Wang, Yong-qing, additional, Liu, Ze-lin, additional, Wu, Jian-wei, additional, Zhang, Xiong, additional, Wu, Bing-yi, additional, Xiao, Ruo-zhi, additional, Wang, San-bin, additional, Li, Jin-yuan, additional, Chi, Pei-dong, additional, Zhang, Qian-yi, additional, Chen, Si-liang, additional, Qin, Zhe-yuan, additional, Zhang, Xin-mei, additional, Zhong, Na, additional, Hiddemann, Wolfgang, additional, Liu, Qi-fa, additional, Zhang, Bei, additional, and Liang, Yang, additional

Published
2021
Full Text
View/download PDF

8. A Simple and Effective Method for Flow Cytometric Study of Lymphoid Malignancies Using Needle Core Biopsy Specimens

Author

Chi, Pei-Dong, primary, Freed, Natalie S., additional, Wake, Laura, additional, Page, Cynthia, additional, Smith, Lynette M., additional, Amador, Catalina, additional, Qureishi, Hina Naushad, additional, Greiner, Timothy C., additional, Rodig, Scott J., additional, Pirruccello, Samuel J., additional, Yuan, Ji, additional, and Fu, Kai, additional

Published
2018
Full Text
View/download PDF

13. Evaluation of diagnostic efficacy of NRP-1/CD304 in hematological diseases.

Author

Liu YJ, Li XH, Song YL, Zhou YC, Cai RZ, and Chi PD

Subjects
Humans, Follow-Up Studies, Prognosis, Acute Disease, Leukemia, Myeloid, Acute diagnosis, Hematologic Diseases, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma genetics, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma metabolism, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Abstract

Background: Previous studies had explored the diagnostic or prognostic value of NRP-1/CD304 in blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and B-cell acute lymphoblastic leukemia (B-ALL), whereas the expression and application value of NRP-1/CD304 in other common hematological diseases have not been reported., Methods: Bone marrow samples from 297 newly diagnosed patients with various hematological diseases were collected to detect the expression of NRP-1/CD304 by flow cytometry (FCM). The diagnostic efficacy of NRP-1/ CD304-positive diseases was analyzed by receiver operating characteristic (ROC) curve, and the area under the ROC curve (AUC) was compared., Results: In the research cohort, the total positive rate of NRP-1/CD304 was 14.81% (44/297), mainly distributed in BPDCN (100%, 6/6), B-ALL (48.61%, 35/72), and AML (4.48%, 3/67), with statistically significant differences (p < 0.01). Other diseases, such as T-cell acute lymphoblastic leukemia (T-ALL), B-cell non-Hodgkin lymphoma (B-NHL), T/NK-cell lymphoma and plasma cell neoplasms, did not express NRP-1/CD304. The AUC of NRP-1/CD304 was 0.936 (95% CI 0.898-0.973), 0.723 (95% CI 0.646-0.801), and 0.435 (95% CI 0.435) in BPDCN, B-ALL and AML, respectively. Besides, CD304 was commonly expressed in B-ALL with BCR-ABL1 gene rearrangement (p = 0.000), and CD304 expression was positively correlated with CD34 co-expression (p = 0.009) and CD10 co-expression (p = 0.007)., Conclusions: NRP-1/CD304 is only expressed in BPDCN, B-ALL and AML, but not in other common hematological diseases. This indicates that NRP-1/CD304 has no obvious diagnostic and follow-up study value in hematological diseases other than BPDCN, B-ALL, and AML., (© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results